Dr Reddy's Laboratories Limited announced on Thursday that the United States Food and Drug Administration has issued final approval for the company's abbreviated New Drug Application for Ciprofloxacin tablets 100 mg, 250 mg, 500 mg and 750 mg.
The company is eligible for 180-days of market exclusively for the 100 mg strength, a company release said.
Ciprofloxacin is the AB-rated generic equivalent of Bayer Corporation's Cipro. Cipro is a broad-spectrum antibiotic, approved for the treatment of several types of infection.